NCT03519386 - Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5% | Biotech Hunter

Enrollment

590

Participants

Timeline

Start Date

July 26, 2018

Primary Completion Date

April 5, 2022

Study Completion Date

April 2, 2024

Conditions

Glaucoma, Open-AngleOcular Hypertension

Interventions

COMBINATION_PRODUCT

G2-TR intraocular implant containing travoprost

Provided in Arm/Group descriptions.

DRUG

Sham surgery + active-comparator eye drops

Sham surgery plus postoperative active-comparator eye drops (timolol maleate ophthalmic solution, 0.5%).

Trial Locations (1)

Vance Thompson Vision, Sioux Falls